Literature DB >> 22134743

Interfering with tumor pathways that augment viral oncolysis.

John C Bell1.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22134743      PMCID： PMC3242672          DOI： 10.1038/mt.2011.253

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  21 in total

1.  The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.

Authors:  Kosei Hasegawa; Takafumi Nakamura; Mary Harvey; Yasuhiro Ikeda; Ann Oberg; Mariangela Figini; Silvana Canevari; Lynn C Hartmann; Kah-Whye Peng
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.

Authors:  Brent J Passer; Tooba Cheema; Bingsen Zhou; Hiroaki Wakimoto; Cecile Zaupa; Mani Razmjoo; Jason Sarte; Shulin Wu; Chin-lee Wu; James W Noah; Qianjun Li; John K Buolamwini; Yun Yen; Samuel D Rabkin; Robert L Martuza
Journal:  Cancer Res       Date:  2010-04-27       Impact factor: 12.701

3.  Poly(A)-binding protein interaction with elF4G stimulates picornavirus IRES-dependent translation.

Authors:  Y V Svitkin; H Imataka; K Khaleghpour; A Kahvejian; H D Liebig; N Sonenberg
Journal:  RNA       Date:  2001-12       Impact factor: 4.942

4.  Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.

Authors:  Jan Brun; Dan McManus; Charles Lefebvre; Kang Hu; Theresa Falls; Harold Atkins; John C Bell; J Andrea McCart; Douglas Mahoney; David F Stojdl
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

5.  A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

Authors:  Jennifer C C Hu; Robert S Coffin; Ceri J Davis; Nicola J Graham; Natasha Groves; Peter J Guest; Kevin J Harrington; Nicholas D James; Colin A Love; Iain McNeish; Louise C Medley; Agnieszka Michael; Christopher M Nutting; Hardev S Pandha; Claire A Shorrock; Julie Simpson; Jan Steiner; Neil M Steven; Dennis Wright; R Charles Coombes
Journal:  Clin Cancer Res       Date:  2006-11-15       Impact factor: 12.531

6.  ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.

Authors:  B L Liu; M Robinson; Z-Q Han; R H Branston; C English; P Reay; Y McGrath; S K Thomas; M Thornton; P Bullock; C A Love; R S Coffin
Journal:  Gene Ther       Date:  2003-02       Impact factor: 5.250

7.  Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Authors:  Thi Lien-Anh Nguyên; Hesham Abdelbary; Meztli Arguello; Caroline Breitbach; Simon Leveille; Jean-Simon Diallo; Amber Yasmeen; Tarek A Bismar; David Kirn; Theresa Falls; Valerie E Snoulten; Barbara C Vanderhyden; Joel Werier; Harold Atkins; Markus J V Vähä-Koskela; David F Stojdl; John C Bell; John Hiscott
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

Review 8.  Measles virus for cancer therapy.

Authors:  S J Russell; K W Peng
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291

Review 9.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15

10.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743
View more
  1 in total

1.  Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Authors:  Diana M Rommelfanger; Phonphimon Wongthida; Rosa M Diaz; Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Richard G Vile
Journal:  Cancer Res       Date:  2012-07-26       Impact factor: 12.701
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.